# A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

> **NCT07389616** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 40 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Cidabenamine, Azacitidine

## Key facts

- **NCT ID:** NCT07389616
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389616, "A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07389616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*